Bone Marrow/Stem Cell Transplant

Investigator-initiated Institutional Protocol

#446-08  PI: VOSE  Coordinator: MAILLIARD, MARY
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma

National Cooperative Group Trial

#181-11  PI: MANESS  Coordinator: HOYT, ROSE
A Phase II Study of Dasatinib (SPRYCEL) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults = 50 Years, with Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG and NCIC CTG (CALGB 10701)

#189-11  PI: BOCIEK  Coordinator: HARDIMAN, PENNY
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) (CALGB 100701-02)

#200-09  PI: COCCIA  Coordinator: OLSON, TAMRA
AAML05P1, Killer Immunoglobulin-Like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7, -5/-5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children’s Oncology Group (COG) Study

Industrial Trial

#274-08  PI: MANESS  Coordinator: HARDIMAN, PENNY
Defibrotide for Hematopoietic Stem Cell Transplant (SCT) Patient with Severe Hepatic Veno Occlusive Disease (VOD): A Treatment IND Study

#312-10  PI: BIERMAN  Coordinator: HARDIMAN, PENNY

Other Externally Peer-Reviewed

#368-11  PI: MANESS  Coordinator: HARDIMAN, PENNY
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

#610-09  PI: FABER  Coordinator: HARDIMAN, PENNY
A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone, and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Versus-Host Disease

#615-09  PI: FABER  Coordinator: HARDIMAN, PENNY
Phase III Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Brain and Neuro. - No Protocols
Breast

**Investigator-initiated Institutional Protocol**

- **#264-12**
  PI: REED
  Coordinator: MAILLIARD, MARY
  A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients with Breast Cancer

- **#371-09**
  PI: REED
  Coordinator: MAILLIARD, MARY
  **A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel with or without Trastuzumab in Stage I-II Breast Cancer Patients**

**National Cooperative Group Trial**

- **#076-12**
  PI: WAHL
  Coordinator: FILLER-KATZ, AMY
  RTOG 1005 A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation plus Sequential Boost For Early-Stage Breast Cancer

- **#167-10**
  PI: FABER
  Coordinator: HARDIMAN, PENNY
  A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (CALGB 70604)

- **#330-12**
  PI: REED
  Coordinator: SHIELDS, KIM
  A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (S1007)

**Industrial Trial**

- **#239-10**
  PI: REED
  Coordinator: SHIELDS, KIM
  A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/NEU Over-Expressing Locally Advanced or Metastatic Breast Cancer
Cervical

National Cooperative Group Trial

#323-12  PI: RODABAUGH  Coordinator: NIELSEN, PAMELA
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial (ANZGOG 0902/GOG-0274/RTOG 1174)

#338-10  PI: WAHL  Coordinator: FILLER-KATZ, AMY
RTOG 0724 - Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Colorectal - No Protocols
Endocrine

**Industrial Trial**

#491-11  
**PI:** GOLDNER  
**Coordinator:** INGRAM, MICHELLE L

**A Multi-Center, Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131 I-Refractory Differentiated Thyroid Cancer**
Endometrial - No Protocols
Esophageal

Investigator-initiated Institutional Protocol

#221-09

PI: GREM

Coordinator: KOS(RICKLEFS), BETH

A Phase II Study of Neo-Adjuvant Therapy with Oxaliplatin, Leucovorin, 5-Flouracil, Panitumumab (Vectibix) and Radiation in Patients with Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Gastrointestinal-Other

National Cooperative Group Trial

#668-10  
**PI:** SCHWARZ  
**Coordinator:** HOYT, ROSE  
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advance Hepatocellular Carcinoma (HCC)

Industrial Trial

#274-08  
**PI:** MANESS  
**Coordinator:** HARDIMAN, PENNY  
Defibrotide for Hematopoietic Stem Cell Transplant (SCT) Patient with Severe Hepatic Veno Occlusive Disease (VOD): A Treatment IND Study
Genitourinary

National Cooperative Group Trial

#381-10  PI: WANG  Coordinator: BURKE, TERRY
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma (CALGB 90601 Updated 5)

#426-09  PI: ABROMOWITCH  Coordinator: OLSON, TAMRA
ARENO321, Treatment of High Risk Renal Tumors (CHMC IRB #487-0706/UNMC 035-10)

Industrial Trial

#026-11  PI: WANG  Coordinator: BURKE, TERRY
A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy
Graft Vs. Host Disease

Other Externally Peer-Reviewed

#610-09  PI: FABER  Coordinator: HARDIMAN, PENNY

A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone, and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Versus-Host Disease
Gynecological-Other

National Cooperative Group Trial

#287-10  PI: RODABAUGH  Coordinator: NIELSEN, PAMELA
A Randomized Phase III Trial with Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV Persistent and Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum, or Ovary (GOG 0261) (NCI Version Date 09/20/2012)
Head/Neck

National Cooperative Group Trial

#170-10  PI: ZHEN  Coordinator: FILLER-KATZ, AMY
A Phase III Study of Postoperative Radiation therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

#529-09  PI: ABROMOWITCH  Coordinator: OLSON, TAMRA
ARAR0331 - Treatment of Childhood Nasopharyngeal Carcinoma with neoadjuvant Chemotherapy and Concomitant Chemotherapy (Children's 603-1108/UNMC 078-10)

#616-11  PI: ZHEN  Coordinator: FILLER-KATZ, AMY
RTOG 1016, Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Heptacellular

**Investigator-initiated Institutional Protocol**

#337-07  
**PI:** LIN  
**Coordinator:** FILLER-KATZ, AMY  
Feasibility of Hypofractionated Stereotactic Radiotherapy in Patients with Hepatocellular Carcinoma

**Multicenter Institutional Protocol**

#406-12  
**PI:** LANGNAS  
**Coordinator:** CARNEY, CAROL  
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)

**National Cooperative Group Trial**

#238-12  
**PI:** ABROMOWITCH  
**Coordinator:** OLSON, TAMRA  
AHEP0731, Treatment of Children with All Stages of Hepatoblastoma

#387-09  
**PI:** ABROMOWITCH  
**Coordinator:** BEROUNSKY, NANCY  
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor (AREN0532) (UNMC 517-08)

#394-09  
**PI:** ABROMOWITCH  
**Coordinator:** BEROUNSKY, NANCY  
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor (AREN0533) (CHMC IRB#519-0307/UNMC 516-08)

#668-10  
**PI:** SCHWARZ  
**Coordinator:** HOYT, ROSE  
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advance Hepatocellular Carcinoma (HCC)
Leukemia

Multicenter Institutional Protocol

#307-12
Pt: MANESS
Coordinator: HOYT, ROSE
Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia

#433-12
Pt: AKHTARI
Coordinator: HOYT, ROSE
A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza) in Patients with Chronic Myelomonocytic Leukemia (CMML)

National Cooperative Group Trial

#017-13
Pt: COCCIA
Coordinator: OLSON, TAMRA
AAML1031 A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC#724772) for Patients with High Allelic Ratio FLT3/ITD

#180-09
Pt: MANESS
Coordinator: HOYT, ROSE
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia

#181-11
Pt: MANESS
Coordinator: HOYT, ROSE
A Phase II Study of Dasatinib (SPRYCEL) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults = 50 Years, with Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG and NCIC CTG (CALGB 10701)

#189-11
Pt: BOCIEK
Coordinator: HARDIMAN, PENNY
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) (CALGB 100701-02)

#200-09
Pt: COCCIA
Coordinator: OLSON, TAMRA
AAML05P1, Killer Immunoglobulin-Like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7, -5/-5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children’s Oncology Group (COG) Study

#232-12
Pt: ABROMOWITCH
Coordinator: OLSON, TAMRA
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

#493-09
Pt: ABROMOWITCH
Coordinator: OLSON, TAMRA
AALL0434, Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (CHMC IRB#515-0207/UNMC 027-08)

#495-12
Pt: ABROMOWITCH
Coordinator: BEROUNSKY, NANCY
ACCL0934 - A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

#509-10
Pt: ABROMOWITCH
Coordinator: OLSON, TAMRA
AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) (UNMC 512-10)

#512-10
Pt: COCCIA
Coordinator: OLSON, TAMRA
AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) (Children's 509-10)

#582-11
Pt: ABROMOWITCH
Coordinator: OLSON, TAMRA
ACCL0933, A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) (UNMC 598-11)

#676-11
Pt: ABROMOWITCH
Coordinator: OLSON, TAMRA
AAML1031, A Phase III Randomized Trial for Patients with De Novo AML using Bortezomib (IND# 58443, NSC# 662481) and Sorafenib (BAY 43-9006, IND# 69433, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD (SRC-PO)

Industrial Trial

#129-11
Pt: MANESS
Coordinator: HOYT, ROSE
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

#198-12
Pt: AKHTARI
Coordinator: HOYT, ROSE
A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo (Vincristine Sulfate Liposomes Injection, VSIL) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects> 60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

#382-12
Pt: BOCIEK
Coordinator: BLUMEL, SUSAN
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Other Externally Peer-Reviewed
Leukemia

Other Externally Peer-Reviewed

#368-11  
PI: MANESS  
Coordinator: HARDIMAN, PENNY

A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
UNMC Eppley Cancer Center Clinical Trials Office
Intervention Protocols by Disease and NCI Priority
3/26/2013

Lung

Investigator-initiated Institutional Protocol

#339-07  Pt: GANTI  Coordinator: KOS(RICKLEFS), BETH
**Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer**

#508-08  Pt: GANTI  Coordinator: KOS(RICKLEFS), BETH
A Phase I Study of Weekly Dose of Vinorelbine and Oral Topotecan for Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC)

Multicenter Institutional Protocol

#524-09  Pt: TRUEMPER  Coordinator: ZINK, MACHELLE A
A Phase III Trial of Calfactant for Acute Lung Injury (ALI) in Pediatric Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Patients

National Cooperative Group Trial

#106-10  Pt: GANTI  Coordinator: TIJERINA, JOLENE M
S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or Without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

#367-07  Pt: KESSINGER  Coordinator: TIJERINA, JOLENE M
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) (E1505 - CTSU)

#588-10  Pt: WAHL  Coordinator: FILLER-KATZ, AMY
RTOG 0937, Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

Industrial Trial

#194-11  Pt: KESSINGER  Coordinator: TIJERINA, JOLENE M
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, Non-Small Cell Lung Cancer (NSCLC)
Lymphoma

**Investigator-initiated Institutional Protocol**

#283-11  
P: VOSE  
Coordinator: BLUMEL, SUSAN  
A Phase 2 Multicenter, Investigator-Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma

#446-08  
P: VOSE  
Coordinator: MAILLIARD, MARY  
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma

#518-10  
P: VOSE  
Coordinator: KRUSE, SUSAN  
**Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma**

**Multicenter Institutional Protocol**

#550-12  
P: BOCIEK  
Coordinator: ALLEN, SUSAN  
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin Lymphoma

**National Cooperative Group Trial**

#704-10  
P: BIERMAN  
Coordinator: BLUMEL, SUSAN  
Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma (CALGB 50604, Update #1)

#718-10  
P: BIERMAN  
Coordinator: ALLEN, SUSAN  
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)

**Industrial Trial**

#131-12  
P: VOSE  
Coordinator: ALLEN, SUSAN  
A Phase 3 Open-Label, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma

#281-11  
P: VOSE  
Coordinator: HOHENSTEIN, MARIBETH  
Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed after Rituximab or Rituximab-Containing Therapy (GSK Protocol: OFB114612)

#312-10  
P: BIERMAN  
Coordinator: HARDIMAN, PENNY  

#416-12  
P: VOSE  
Coordinator: HOHENSTEIN, MARIBETH  
A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy

#628-12  
P: VOSE  
Coordinator: ALLEN, SUSAN  
A Phase I Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies

#629-12  
P: BOCIEK  
Coordinator: HOHENSTEIN, MARIBETH  
A Phase I/II Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)
MDS - No Protocols
Melanoma/Other Skin

National Cooperative Group Trial

#092-12  PI: MARR  Coordinator: TJERINA, JOLENE M

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon α-2b For Resected High-Risk Melanoma
Multiple Myeloma

National Cooperative Group Trial

#167-10  PI: FABER  Coordinator: HARDIMAN, PENNY
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (CALGB 70604)

Industrial Trial

#147-12  PI: FABER  Coordinator: HARDIMAN, PENNY
A Phase III, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma

#501-11  PI: FABER  Coordinator: HARDIMAN, PENNY
Carfilzomib Multiple Myeloma Expanded Access Protocol (C-MAP) for Patients with Relapsed and Refractory Disease (Protocol 2011-002)

#633-12  PI: FABER  Coordinator: HARDIMAN, PENNY
A Multi-Center, Single-Arm, Open-Label Treatment Use Program for Pomalidomide (POM) in Combination with Low Dose Dexamethasone (LD-DEX) in Subjects with Relapsed or Refractory Multiple Myeloma.

Other Externally Peer-Reviewed

#615-09  PI: FABER  Coordinator: HARDIMAN, PENNY
Phase III Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Other-Fungal Infections

National Cooperative Group Trial

#582-11  PI: ABROMOWITCH  Coordinator: OLSON, TAMRA
ACCL0933, A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) (UNMC 598-11)
Other-Post BMT for VOD

Industrial Trial

#274-08  PI: MANESS  Coordinator: HARDIMAN, PENNY
Defibrotide for Hematopoietic Stem Cell Transplant (SCT) Patient with Severe Hepatic Veno Occlusive Disease (VOD): A Treatment IND Study
Other-Spine

National Cooperative Group Trial

#582-09  PI: WAHL  Coordinator: FILLER-KATZ, AMY
RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis
Ovarian

National Cooperative Group Trial

#008-06

PI: RODABAUGH

Coordinator: NIELSEN, PAMELA

A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177) Versus No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy (GOG 212) NCI Version: 08/18/11
Pancreatic

Investigator-initiated Institutional Protocol

#441-07  PI: LIN  Coordinator: KOS(RICKLEFS), BETH
A Phase I Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients with Locally Advanced Pancreatic Cancer

Industrial Trial

#248-10  PI: GREM  Coordinator: TJERINA, JOLENE M
A Phase III Study of Chemotherapy and Chemoradiotherapy with or without Hyperacute-Pancreas (algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer (NLG0405)
Prostate

Investigator-initiated Institutional Protocol

#479-09  PI: WANG  Coordinator: KRUSE, SUSAN
**A Phase I/II Clinical Trial of Lenalidomide in Combination with Oral Cyclophosphamide in Patients with Previously Treated Hormone Refractory Prostate Cancer

National Cooperative Group Trial

#066-10  PI: WAHL  Coordinator: FILLER-KATZ, AMY
(RTOG 0815) A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer

#167-10  PI: FABER  Coordinator: HARDIMAN, PENNY
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (CALGB 70604)

#570-12  PI: WAHL  Coordinator: FILLER-KATZ, AMY
RTOG 1115 Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with GNRH Agonist and TAK-700 for Men with High Risk Prostate Cancer

Industrial Trial

#635-12  PI: WANG  Coordinator: BURKE, TERRY
A Phase 3, Randomized, Double-Blind, Controlled Trial of Cabozantinib (XL184) Vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-Resistant Prostate Cancer
Sarcoma

National Cooperative Group Trial

#003-13  
**PI:** SHONKA  
**Coordinator:** HOYT, ROSE  
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma (A091102)

#581-11  
**PI:** ABROMOWITCH  
**Coordinator:** OLSON, TAMRA  
ARST0921, A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/ Refractory Rhabdomyosarcoma (UNMC 597-11)